Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
基本信息
- 批准号:9196058
- 负责人:
- 金额:$ 194.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-30 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:BloodCadmiumCardiovascular DiseasesCardiovascular systemChelation TherapyClinicalClinical TrialsCompanionsCreatinineDataDevelopmentDiabetes MellitusDoseElementsEnrollmentEnsureEnvironmentEpidemiologyEvaluationEventExcretory functionFundingFutureGrantHalf-LifeHumanIndividualInfusion proceduresLeadLead levelsMeasurementMeasuresMediatingMetalsMethodsMultivitaminMyocardial InfarctionOralOutcomeParticipantPatientsPatternPhasePlacebosPlasmaRecording of previous eventsRoleSamplingSecureSolidSpecimenTechniquesTestingUrineWhole BloodWorkabstractingarmbasebiobankblood leadbonecardiovascular risk factorcausal modelchelationclinically significantdiabetic patientimprovedinnovationlead exposurepredict clinical outcomeprognostic significancerandomized trialsoft tissuetoxic metaltreatment duration
项目摘要
Project Summary/Abstract
The main objectives of the Metals in the Trial to Assess Chelation Therapy 2 (TACT2M) are to evaluate
whether long-term edetate disodium (EDTA)-based chelation infusions can significantly reduce body lead and
cadmium levels and to determine whether this effect explains the reduction in major cardiovascular events
caused by EDTA chelation therapy. TACT2M is a companion study to TACT2 and will be integrated into the
clinical trial platform of TACT2, which will enroll 1200 post-MI patients with diabetes who are at least 50 years
old and have a creatinine of 2.0 mg/dL or less. TACT2, a replication study of TACT (referred to as TACT1), will
be a 2X2 factorial trial, randomizing patients to 4 groups, defined by both active vs placebo infusions and
active vs placebo oral multivitamins and multiminerals (OMVM). NCCIH has funded the UG3 1-year Planning
Phase of TACT2. The co-primary endpoints of TACT2M are: 1] the change in blood lead level from baseline to
infusion 40 or 1 year, whichever is first, and 2] the change in urine cadmium controlled for creatinine (Cd mcg/
gram creatinine) from baseline to infusion 40 or 1 year, whichever is first.
TACT2M has 3 Specific Aims: 1] Compare the change in metal internal dose (blood lead and urine cadmium)
in TACT2 participants, from baseline to infusion 40 or 1 year in the active infusion arm; 2] Evaluate whether
higher baseline metal internal dose (blood lead and urine cadmium) and the extent of depletion of those stores
identifies patients more likely to show benefit from chelation; 3] Collect a biorepository of specimens to support
future mechanistic work. Samples of whole blood and urine will be stored at -80ºC in a secured biorepository to
ensure their availability for the evaluation of future hypotheses that will be guided by the results of the trial.
Moreover, TACT2M represents a unique opportunity to assess the following Exploratory Aims: a] whether post-
infusion urine measurements, alone and in comparison to the corresponding pre-infusion measurements, have
clinical significance; b] whether OMVM interact with edetate disodium-mediated metal excretion; and c]
whether the suite of additional toxic and essential metals measured in blood and urine by the ICPMS analytic
technique used by the metals lab, many of which are not chelated by edetate disodium, have clinical
significance in preliminary testing.
In summary, TACT2M will assess whether metal chelation is a possible mechanism for improved clinical
outcomes in post-MI diabetic patients receiving edetate disodium chelation. The integration of TACT2M into
the existing TACT2 study is an efficient method to inform the treatment of patients with a history of MI and
diabetes.
项目总结/摘要
评估螯合疗法2(TACT 2 M)试验中的金属的主要目的是评估
长期的基于乙二胺四乙酸二钠(EDTA)的螯合输注是否可以显著降低体内铅含量,
镉水平,并确定这种效应是否可以解释主要心血管事件的减少
是EDTA螯合疗法引起的TACT 2 M是TACT 2的伴随研究,将被整合到
TACT 2的临床试验平台,将入组1200例年龄至少50岁的MI后糖尿病患者
年龄较大,肌酐≤ 2.0 mg/dL。TACT 2是TACT(简称TACT 1)的重复研究,
是一项2X2析因试验,将患者随机分为4组,定义为活性药物输注与安慰剂输注,
活性与安慰剂口服多种维生素和多种矿物质(OMVM)。NCCIH资助了UG 3 1年规划
TACT 2阶段。TACT 2 M的协同主要终点是:1]血铅水平从基线至
输注40年或1年,以先发生者为准,2]肌酐控制的尿镉变化(Cd mcg/
g肌酐),以先发生者为准。
TACT 2 M有3个具体目的:1)比较金属内剂量(血铅和尿镉)的变化
在TACT 2受试者中,活性输注组从基线至输注40年或1年; 2]评价是否
较高的基线金属体内剂量(血铅和尿镉)和这些储存的消耗程度
确定患者更有可能从螯合治疗中获益; 3]收集标本的生物储存库,以支持
未来的机械化工作。全血和尿液样本将在-80播放C下储存在安全的生物储存库中,
确保其可用于评估未来的假设,这些假设将以试验结果为指导。
此外,TACT 2 M是评估以下探索性目标的独特机会:
单独的输注尿液测量值以及与相应的输注前测量值相比,
临床意义; B] OMVM是否与依地酸二钠介导的金属排泄相互作用;和c]
通过ICPMS分析仪在血液和尿液中测量的其他有毒和必需金属套件是否
金属实验室使用的技术,其中许多不被乙二胺四乙酸二钠螯合,
初步测试的意义。
总之,TACT 2 M将评估金属螯合是否是改善临床症状的可能机制。
接受依地酸二钠螯合治疗的MI后糖尿病患者的结局。将TACT 2 M整合到
现有的TACT 2研究是告知有MI病史患者治疗的有效方法,
糖尿病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GERVASIO A LAMAS其他文献
GERVASIO A LAMAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GERVASIO A LAMAS', 18)}}的其他基金
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
- 批准号:
10388645 - 财政年份:2016
- 资助金额:
$ 194.58万 - 项目类别:
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
- 批准号:
9688920 - 财政年份:2016
- 资助金额:
$ 194.58万 - 项目类别:
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
- 批准号:
10254152 - 财政年份:2016
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
9551736 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
9693679 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
9181934 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
9144714 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
10390527 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
9357528 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
- 批准号:
10260378 - 财政年份:2015
- 资助金额:
$ 194.58万 - 项目类别:
相似国自然基金
Vimentin构象改变与自噬的相互调控在Cadmium致血睾屏障破坏作用中的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Supplement for Role of Environmental Weathering and Gastrointestinal Digestion on the Bioavailability and Toxicity of Microplastic and Cadmium Mixtures
补充环境风化和胃肠消化对微塑料和镉混合物的生物利用度和毒性的作用
- 批准号:
10854398 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
Sensory Mechanisms of Cadmium-Induced Behavioral Disorders Across Generations
镉引起的几代人行为障碍的感觉机制
- 批准号:
10747559 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
Environmental Cadmium, persistent inflammation and airways disease
环境镉、持续性炎症和气道疾病
- 批准号:
10637234 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
The Rapid-Production of the High-Performance and Affordable Cadmium Telluride and Cadmium Zinc Telluride for Medical Imaging Applications.
快速生产用于医学成像应用的高性能且经济实惠的碲化镉和碲化镉锌。
- 批准号:
10761330 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
Cadmium and Arsenic Effects on Pyrimidine Biosynthesis in Early Airway Development
镉和砷对早期气道发育中嘧啶生物合成的影响
- 批准号:
10568094 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
Comprehensive investigations and health measures for inhabitants in cadmium-polluted areas in Akita prefecture and expansion of them to cadmium-polluted areas in Toyama prefecture.
对秋田县镉污染地区居民进行全面调查和健康措施,并将调查范围扩大到富山县镉污染地区。
- 批准号:
23H03169 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Reducing study time for rest/stress 99mTc-tetrofosmin myocardial perfusion imaging with myocardial blood flow measurement using cadmium-zinc-telluride camera imaging
使用碲化镉锌相机成像测量心肌血流量,缩短休息/应激 99mTc-替曲膦心肌灌注成像的研究时间
- 批准号:
480733 - 财政年份:2023
- 资助金额:
$ 194.58万 - 项目类别:
Collaborative Research: RUI: An In-depth Characterization of Divalent Cadmium Binding to Human Cardiac Troponin C and the Impact on Subsequent Protein Interactions
合作研究:RUI:二价镉与人心肌肌钙蛋白 C 结合的深入表征以及对后续蛋白质相互作用的影响
- 批准号:
2203467 - 财政年份:2022
- 资助金额:
$ 194.58万 - 项目类别:
Standard Grant
Sensory Mechanisms of Cadmium-Induced Behavioral Disorders Across Generations
镉引起的几代人行为障碍的感觉机制
- 批准号:
10607195 - 财政年份:2022
- 资助金额:
$ 194.58万 - 项目类别:
Effects of cadmium on tight junction of vascular endothelial cells: clarification of the mechanism of detachment injury
镉对血管内皮细胞紧密连接的影响:阐明脱离损伤机制
- 批准号:
22K17355 - 财政年份:2022
- 资助金额:
$ 194.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists